Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

428 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characteristics of patients with diabetes and a history of myocardial infarction initiating PCSK9 and SGLT2 inhibitors.
Hubbard D, McKinley EC, Colantonio LD, Poudel B, Rosenson RS, Brown TM, Jackson EA, Huang L, Orroth KK, Mues KE, Dluzniewski PJ, Bittner V, Muntner P. Hubbard D, et al. Among authors: rosenson rs. Am Heart J Plus. 2022 Mar 24;13:100121. doi: 10.1016/j.ahjo.2022.100121. eCollection 2022 Jan. Am Heart J Plus. 2022. PMID: 38560067 Free PMC article.
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceška R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA; GAUSS-3 Investigators. Nissen SE, et al. Among authors: rosenson rs. JAMA. 2016 Apr 19;315(15):1580-90. doi: 10.1001/jama.2016.3608. JAMA. 2016. PMID: 27039291 Clinical Trial.
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.
Rosenson RS, Gaudet D, Hegele RA, Ballantyne CM, Nicholls SJ, Lucas KJ, San Martin J, Zhou R, Muhsin M, Chang T, Hellawell J, Watts GF; ARCHES-2 Trial Team. Rosenson RS, et al. N Engl J Med. 2024 May 29. doi: 10.1056/NEJMoa2404147. Online ahead of print. N Engl J Med. 2024. PMID: 38809174
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.
Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, Melquist S, Zhou R, Mushin M, Leeper NJ, Hellawell J, Gaudet D. Ballantyne CM, et al. Among authors: rosenson rs. N Engl J Med. 2024 May 28. doi: 10.1056/NEJMoa2404143. Online ahead of print. N Engl J Med. 2024. PMID: 38804517
428 results